Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Ph Gabriel Steg, & on behalf of the SCORED Investigators. (2023). SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL. Elsevier.
Chicago Style (17th ed.) CitationDeepak L. Bhatt, Michael Szarek, Bertram Pitt, Ph Gabriel Steg, and on behalf of the SCORED Investigators. SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL. Elsevier, 2023.
MLA (9th ed.) CitationDeepak L. Bhatt, et al. SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL. Elsevier, 2023.
Warning: These citations may not always be 100% accurate.